U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

10/28/200 02 FC:181 Docket Number (Optional)

KLULO HON OVER AFRION FAILER	
In re Application of: ONOVAN	7
Application No.: 09/706211	
Filed: November 2,2000 For: method for treating thyroid disorders with a botilinum to xin	
The owner*, ACCERGAN, INC., of loo percent interest in the instant application hereb disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 6319506. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the granted its successors or assigns.	n, y nt e
In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instal application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, of is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.	ie a in or
Check either box 1 or 2 below, if appropriate.	ہر
For submissions on behalf of an organization (e.g., corporation, partnership, university, government agence etc.), the undersigned is empowered to act on behalf of the organization.	<b>( )</b>
I hereby declare that all statements made herein of my own knowledge are true and that all statements made or information and belief are believed to be true; and further that these statements were made with the knowledge that willfur false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 or the United States Code and that such willful false statements may jeopardize the validity of the application or any patentissued thereon.	i de
2. The undersigned is an attorney or agent of record.	
3 TLUU11 00000089 010885 09706211 Signature Date	
4 110.00 DA STEPHEN DONOVAN	
Typed or printed name	
714 246 4026 Telephone Number	
▼ Terminal disclaimer fee under 37 CFR 1.20(d) included. — Charge deposit account 01 - 085	
WARNING: Information on this form may become public. Credit card Information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A PRIOR PATENT

Docket Number (Optional)

411	REJECTION OVER A PRIOR PATENT	
	In re Application of: ONOVAN	
·	Application No.: 09/706all	ń
٠.	First Nickelland 2 2 2 2 2	
•	Filed: November 2,2000 For method for treating thy road disorders with a botulinum to xin	
	The owner*, ACCERGAN, INC., of UO percent interest in the instant application hereby	*,
	I with a later and an arguided helevy, the terminal hart of the statility lettin of any balletic digitized off the instant appropriety in	
	which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 134 and 173, as presently i	
	shortened by any terminal disclaimer, of prior Patent No. 63 28 977. The owner hereby agrees that any patent are	
	so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee,	
	its successors or assigns.	
	In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant	
	application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the	
	I prior notant as presently shortened by any terminal disclaimer, in the event that it later: expires for latitude to pay a	
	I maintanance fee is held unenforceable is found invalid by a court of competent jurisdiction, is statutorily disciallifed in	
•	I whale or terminally disclaimed under 37 CFR 1 321 has all claims canceled by a reexamination certificate, is reissued, or	<b>A</b> .
	is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal	
. *	disclaimer.	
	Quantization have deep 2 halous if appropriate	37700
	Check either box 1 or 2 below, if appropriate.	رتنا
٠.	For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency)	17/2
	etc.), the undersigned is empowered to act on behalf of the organization.	
	to the statements made on	En.
	I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful information and belief are believed to be true; and further that these statements were made with the knowledge that willful	200
	I folce electroments and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 10 of	10
	the United States Code and that such willful false statements may jeopardize the validity of the application or any patent	
	issued thereon.	}
	2. The undersigned is an attorney or agent of record.	· )
	> Upon 10 (16/03	,
	Signature Date	
10/20/20		
	_ IE, HEN JONOVA	
03 FC:18	14 110.00 DA Typed or printed name	1
•	714 246 4026	*
	Telephone Number	1
	▼ Terminal disclaimer fee under 37 CFR 1.20(d) included. — Charge deposit account 01 - 0855	<b>~</b>
	WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
	*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).	· .
	Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief-Information-Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/26 (08-03)
Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Understhe Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING
REJECTION OVER A PRIOR PATENT

Docket Number (Optional)

	RESERVICE COLORS
	In re Application of: ONOVAN
1	Application No.: 09/706au
	Filed: November 2,200 thyrod disorders with a botulinum to xin
	The owner*, ALLERGAN, INC., of Opercent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173, as presently shortened by any terminal disclaimer, of prior Patent No. 63585/3. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.
	In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of the prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.
	Check either box 1 or 2 below, if appropriate.
	1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.
	I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.
	2. The undersigned is an attorney or agent of record.
	Signature Date
/28/2003	TLUU11 00000089 010885 09706211 STEPHEN DONOVAN TO
FC:1814	110.00 DA Typed or printed name
*	714 246 4026
	Telephone Number
	I Terminal disclaimer fee under 37 CFR 1.20(d) included Charge deposit account 01 - 0855
	WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card Information and authorization on PTO-2038.
	*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).  Form PTO/SB/96 may be used for making this certification. See MPEP § 324.
,	This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief-Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/26 (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING

**Docket Number (Optional)** 

	REJECTION OVER A PRIOR PATENT	1734101VI
	In re Application of: ONOVAN	
	A Broken May DG I and (DA)	
	Filed: November 2,200 For: Method for treating thyroid disorders with a bo-	tulinum to xin
	The owner*, ACCERGAN, INC., of	d on the instant application, 154 and 173, as presently reby agrees that any patent it it and the prior patent are is binding upon the grantee,
	In making the above disclaimer, the owner does not disclaim the terminal part of any application that would extend to the expiration date of the full statutory term as defined in 35 prior patent, as presently shortened by any terminal disclaimer, in the event that it later: maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexaminati is in any manner terminated prior to the expiration of its full statutory term as presently disclaimer.	expires for failure to pay a n, is statutorily disclaimed in on certificate, is reissued, or
	Check either box 1 or 2 below, if appropriate.	
	1. For submissions on behalf of an organization (e.g., corporation, partnership, universit etc.), the undersigned is empowered to act on behalf of the organization.	y, government agency,
	I hereby declare that all statements made herein of my own knowledge are true and information and belief are believed to be true; and further that these statements were made w false statements and the like so made are punishable by fine or imprisonment, or both, unde the United States Code and that such willful false statements may jeopardize the validity of t issued thereon.	r Section 1001 of Title 18 of
	2. The undersigned is an attorney or agent of record.  Signature	10/16/03 Date 3
10/28/2003	TLUU11 00000089 010885 09706211 STEPHEN	DONOVAID
05 FC:1814	· · · · · · · · · · · · · · · · · · ·	printed name
	714 246 o	rinted name  4026  Number
	Terminal disclaimer fee under 37 CFR 1.20(d) included. — Charge deposit	
	WARNING: Information on this form may become public. Credit card information be included on this form. Provide credit card information and authorization on P	should not
.*.	*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (ov Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or-suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/26 (08-03) Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. TERMINAL DISCLAIMER TO OBVIATE A DOUBLE PATENTING

Docket Numb r (Optional)

- [	REJECTION OVER A PRIOR PATENT	
	In re Application of: ONOVAN	
	Application No.: 09/706211	
	Filed: November 2,200 thyroid disorders with a botulinum to xin For: method for treating thyroid disorders with a botulinum to xin	
İ		
	disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173, as preser shortened by any terminal disclaimer, of prior Patent No. 656770. The owner hereby agrees that any pat so granted on the instant application shall be enforceable only for and during such period that it and the prior patent commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grant its successors or assigns.	on, ntly ent are tee,
	In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instance application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 and 173 of prior patent, as presently shortened by any terminal disclaimer, in the event that it later: expires for failure to paraintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed whole or terminally disclaimed under 37 CFR 1.321, has all claims canceled by a reexamination certificate, is reissued is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any term disclaimer.	une aya dir d, o
ł	Check either box 1 or 2 below, if appropriate.	
	1. For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.	
·	I hereby declare that all statements made herein of my own knowledge are true and that all statements made information and belief are believed to be true; and further that these statements were made with the knowledge that wi false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 the United States Code and that such willful false statements may jeopardize the validity of the application or any paissued thereon.	illiu 8 o
	2. The undersigned is an attorney or agent of record.  Signature  Date	<u> </u>
	/ Signaturo	3
2003	TLUU11 00000089 010885 09706211 STEPHEN OONOVAN'  Typed or printed name	20
1814	110.00 DA	3
	114 246 4026	_
	Telephone Number	_
	▼ Terminal disclaimer fee under 37 CFR 1.20(d) included. — Charge deposit account 01 - 0	8
	WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.	
	*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner).  Form PTO/SB/96 may be used for making this certification. See MPEP § 324.	

This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING

Docket Number (Optional)

CHILE

REJECTION OVER A PENDING SECOND APPLICATION	1734101VI
In re Application of: DONOVAN	TO C
Application No.: 09/706211	Ch
Filed: November 2, 2000	110
Application No.: 09/706211  Filed: November 2, 2000  For: Method for treating thy rold disorders with  The owner*, ALLERGAN INC. of 100 percent interest in the instant application	toxing
beyond the expiration date of the full statutory term of any patent granted on the instant approvided below, the expiration date of the full statutory term defined in 35 U.S.C. 154 and 173 a disclaimer filed prior to the grant of any patent granted on pending second Application Number of the instant application shall be enforceable only for and during such period that it second application are commonly owned. This agreement runs with any patent granted on binding upon the grantee, its successors or assigns.	as shortened by any terminal mber 09 / 706/72, eby agrees that any patent so and any patent granted on the the instant application and is
In making the above disclaimer, the owner does not disclaim the terminal part of an application that would extend to the expiration date of the full statutory term as defined in a patent granted on the second application, as shortened by any terminal disclaimer filed prevent that any such granted patent: expires for failure to pay a maintenance fee, is held une a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed claims canceled by a reexamination certificate, is reissued, or is in any manner terminated patents to the statutory term as shortened by any terminal disclaimer filed prior to its grant.	35 U.S.C. 154 and 173 of any ior to the patent grant, in the inforceable, is found invalid by under 37 CFR 1.321, has all
Check either box 1 or 2 below, if appropriate.	
1. For submissions on behalf of an organization (e.g., corporation, partnership, universetc.), the undersigned is empowered to act on behalf of the organization.	ersity, government agency,
I hereby declare that all statements made herein of my own knowledge are true an information and belief are believed to be true; and further that these statements were made false statements and the like so made are punishable by fine or imprisonment, or both, und the United States Code and that such willful false statements may jeopardize the validity of issued thereon.	with the knowledge that willful ler Section 1001 of Title 18 of
2. The undersigned is an attorney or agent of record.	DIE 10/16/03
TLUU11 00000089 010885 09706211	Date
110.00 DA STEPHEN O	UAVOINO
Typed or prin	Reg No. 33, 433
714 246 4	0 26 9 Number
[7]	
Terminal disclaimer fee under 37 CFR 1.20(d) is included. — Charge Alpas	it account 01-0885

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

\*Statement under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this statement. See MPEP § 324.

10/28/2003 07 FC:1814

> This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. - Confidentiality is governed by 35 U.S.C.-122 and 37 CFR-1.14. - This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.